E. Klimov, N. Kondratieva, A. Anuchina, K. Skorobogatykh, J. Azimova, A. Sergeev, Elena A Naumova, O. Rudko, Z. Kokaeva, A. Soboleva, V. Sobolev, G. Tabeeva
{"title":"偏头痛的遗传学-有进展吗?","authors":"E. Klimov, N. Kondratieva, A. Anuchina, K. Skorobogatykh, J. Azimova, A. Sergeev, Elena A Naumova, O. Rudko, Z. Kokaeva, A. Soboleva, V. Sobolev, G. Tabeeva","doi":"10.15406/JNSK.2017.07.00245","DOIUrl":null,"url":null,"abstract":"Until now, the diagnosis of “migraine” is exclusively clinical, and any diagnostic tests are aimed only at excluding other causes of headache [4]. There are also problems with migraine treatment and although both traditional analgesics and specific anti-migraine products are available in the market, treatment of migraine patients is still not sufficiently effective. For example, specific anti-migraine agents (triptans) help control only two out of three attacks, and migraine prevention products are considered effective, if they reduce the frequency of attacks by 50% or more. The chronification of migraine attacks and the development of chronic daily headaches, occurring in 1% of patients per year [5], are a significant clinical problem. However, about 10% of migraine patients in the population and 40-60% of patients visiting specialized headache centers are resistant to standard therapy [6]. Treatment of such patients is the most expensive.","PeriodicalId":106839,"journal":{"name":"Journal of Neurology and Stroke","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Genetics of Migraine - Is There any Progress?\",\"authors\":\"E. Klimov, N. Kondratieva, A. Anuchina, K. Skorobogatykh, J. Azimova, A. Sergeev, Elena A Naumova, O. Rudko, Z. Kokaeva, A. Soboleva, V. Sobolev, G. Tabeeva\",\"doi\":\"10.15406/JNSK.2017.07.00245\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Until now, the diagnosis of “migraine” is exclusively clinical, and any diagnostic tests are aimed only at excluding other causes of headache [4]. There are also problems with migraine treatment and although both traditional analgesics and specific anti-migraine products are available in the market, treatment of migraine patients is still not sufficiently effective. For example, specific anti-migraine agents (triptans) help control only two out of three attacks, and migraine prevention products are considered effective, if they reduce the frequency of attacks by 50% or more. The chronification of migraine attacks and the development of chronic daily headaches, occurring in 1% of patients per year [5], are a significant clinical problem. However, about 10% of migraine patients in the population and 40-60% of patients visiting specialized headache centers are resistant to standard therapy [6]. Treatment of such patients is the most expensive.\",\"PeriodicalId\":106839,\"journal\":{\"name\":\"Journal of Neurology and Stroke\",\"volume\":\"27 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurology and Stroke\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/JNSK.2017.07.00245\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology and Stroke","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/JNSK.2017.07.00245","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Until now, the diagnosis of “migraine” is exclusively clinical, and any diagnostic tests are aimed only at excluding other causes of headache [4]. There are also problems with migraine treatment and although both traditional analgesics and specific anti-migraine products are available in the market, treatment of migraine patients is still not sufficiently effective. For example, specific anti-migraine agents (triptans) help control only two out of three attacks, and migraine prevention products are considered effective, if they reduce the frequency of attacks by 50% or more. The chronification of migraine attacks and the development of chronic daily headaches, occurring in 1% of patients per year [5], are a significant clinical problem. However, about 10% of migraine patients in the population and 40-60% of patients visiting specialized headache centers are resistant to standard therapy [6]. Treatment of such patients is the most expensive.